Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + finolitimab + bevacizumab
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capecitabine + finolitimab + bevacizumab is a combination therapeutic regimen being investigated as an adjuvant treatment for patients with high-risk biliary tract cancer (BTC) following surgical resection. The regimen consists of capecitabine, an oral fluoropyrimidine carbamate that acts as a prodrug of 5-fluorouracil (5-FU); finolitimab (also known as serplulimab or HLX10), a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor; and bevacizumab, a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). This combination strategy aims to leverage the cytotoxic activity of chemotherapy, the restoration of anti-tumor immune responses via checkpoint inhibition, and the inhibition of angiogenesis to reduce the risk of postoperative recurrence. It is currently being evaluated in a Phase II clinical trial (ChiCTR2500112470) led by West China Hospital.
- Brand names
- Hansizhuang
- Other names
- capecitabine + serplulimab + bevacizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on capecitabine + finolitimab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + finolitimab + bevacizumab.